Mitochondrial Dysfunction Hub
Overview
This hub serves as the central navigation point for all mitochondrial dysfunction content in NeuroWiki. Mitochondrial dysfunction is one of the most consistently observed pathological features across neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Huntington's disease](/mechanisms/huntington-pathway), and the [tauopathies](/diseases/corticobasal-degeneration) including [CBS/PSP](/diseases/progressive-supranuclear-palsy).
The brain, comprising approximately 2% of body mass but consuming ~20% of oxygen and glucose, is exquisitely vulnerable to mitochondrial disruptions. Neurons are particularly susceptible due to their post-mitotic nature, high metabolic demands, and limited glycolytic capacity[@guzman2024].
Pathophysiological Mechanisms
Electron Transport Chain Defects
The electron transport chain (ETC) is the primary site of mitochondrial dysfunction across neurodegenerative diseases. Complex I (NADH:ubiquinone oxidoreductase) deficiency is the most consistently observed abnormality, particularly in [Parkinson's disease](/diseases/parkinsons-disease)[@schapira2020]. Multiple mechanisms contribute to ETC dysfunction:
Complex I deficiency:
- Rotenone and MPTP exposure recapitulate PD features in models
- PINK1 and PARK2 mutations impair Complex I function
- mtDNA mutations affect Complex I subunits
- Post-translational modifications (oxidation, nitration) impair activity
Complex III and IV defects:
- Accumulation of damaged mtDNA affects complex assembly
- Amyloid-beta directly inhibits Complex IV in [Alzheimer's disease](/diseases/alzheimers-disease)
- Tau pathology disrupts mitochondrial transport to synapses[@jiang2024]
Reactive Oxygen Species and Oxidative Stress
Mitochondrial dysfunction leads to excessive reactive oxygen species (ROS) production, creating a vicious cycle of oxidative damage[@johri2023]:
ROS sources in neurodegeneration:
- Electron leak from Complex I and III
- Monoamine oxidase activity in dopaminergic neurons
- Iron accumulation in substantia nigra
- Inflammatory glial cell activation
Consequences of oxidative stress:
- Lipid peroxidation (malondialdehyde, 4-hydroxynonenal)
- Protein oxidation (carbonylation, nitration)
- mtDNA mutations and deletions
- Activation of cell death pathways
Calcium Dysregulation
Mitochondria serve as critical calcium buffers, and their dysfunction disrupts cellular calcium homeostasis[@gandhi2023]:
Calcium handling defects:
- Impaired mitochondrial calcium uptake (mCU/MCU)
- Reduced calcium extrusion (mNCLX)
- Altered mitochondrial permeability transition pore (mPTP)
- Disrupted calcium signaling to nucleus
Impact on neuronal function:
- Excitotoxicity through NMDA receptor overactivation
- Calpain activation and proteolysis
- Impaired synaptic plasticity
- Activation of apoptotic pathways
Mitochondrial DNA Damage
The brain accumulates mtDNA mutations with aging, and this burden is amplified in neurodegenerative diseases[@mittal2023]:
mtDNA alterations in neurodegeneration:
- Point mutations and deletions in neurons
- Reduced mtDNA copy number
- Impaired mtDNA repair (base excision repair defects)
- 3243A>G mutation in MELAS syndrome with parkinsonism
Different neuronal populations show varying susceptibility to mitochondrial dysfunction[@wang2024]:
Dopaminergic neurons:
- High metabolic demand for dopamine synthesis
- Complex I deficiency in substantia nigra
- Iron accumulation promoting oxidative stress
- Limited antioxidant capacity
Cortical pyramidal neurons:
- Large axonal arbors requiring extensive mitochondria
- Amyloid-beta and tau impact on mitochondrial transport
- High calcium influx during synaptic activity
Therapeutic Approaches
Mitochondrial-Targeted Interventions
Multiple therapeutic strategies aim to restore mitochondrial function:
Antioxidants:
- Coenzyme Q10 (electron carrier and antioxidant)
- MitoQ (mitochondria-targeted ubiquinone)
- MitoTEMPO (mitochondria-targeted superoxide dismutase mimetic)
- Vitamin E and N-acetylcysteine
Metabolic support:
- Alpha-lipoic acid (energy metabolism cofactor)
- Creatine (ATP buffer)
- Pyruvate dehydrogenase activators
- Ketone supplementation
Quality control enhancement:
- PINK1-Parkin pathway activators
- Autophagy inducers (rapamycin, metformin)
- Mitochondrial dynamics modulators
- mitochondrial-derived vesicle targeting
Emerging Therapies
Pharmacological approaches:
- PGC-1alpha agonists for mitochondrial biogenesis
- SIRT1/3 activators for metabolic regulation
- mTOR inhibitors for autophagy enhancement
- GLP-1 receptor agonists with mitochondrial effects
Gene therapy:
- Mitochondrial-targeted gene delivery
- MT-ND genes for Complex I restoration
- TFAM for mtDNA maintenance
- PINK1/PARK2 expression optimization
Cell-based approaches:
- Mitochondrial transplantation
- Stem cell-derived neuronal replacement
- Mitochondrial-rich extracellular vesicles
Mouse Models of Mitochondrial Dysfunction
Genetic Models
PD models:
- PINK1 knockout mice (subtle phenotype without stress)
- PARK2 knockout mice (age-related dopaminergic loss)
- PINK1/PARK2 double knockout (robust degeneration)
- Mitochondrial DNA mutation models
AD models:
- 3xTg-AD (APP, Tau, PS1 mutations)
- APP/PS1 models (amyloid-driven mitochondrial dysfunction)
- Tau P301L models (tau pathology effects)
- mtDNA mutator mice (accelerated aging)[@shen2024]
ALS models:
- SOD1 G93A transgenic mice
- TDP-43 transgenic models
- C9orf72 BAC models
Toxin Models
- MPTP (Complex I inhibitor) — acute and chronic models
- Rotenone (Complex I inhibitor) — systemic model
- 6-OHDA (dopaminergic toxin)
- Kainic acid (excitotoxic model)
- Chronic mild stress models
Limitations
- Species differences in mitochondrial biology
- Incomplete recapitulation of human disease
- Strain-dependent phenotypes
- Environmental factor interactions
Biomarkers of Mitochondrial Dysfunction
Fluid Biomarkers
Blood markers:
- Mitochondrial DNA copy number
- Circulating mtDNA fragments
- Cell-free mitochondrial peptides
- Mitochondrial-derived vesicles
CSF markers:
- Mitochondrial proteins (TFAM, COXVIII)
- Lactate and pyruvate
- Neurofilament light chain (NfL)
- Mitochondrial-specific metabolites
Imaging Biomarkers
- PET ligands for mitochondrial function
- MR spectroscopy (lactate, N-acetylcysteine)
- Diffusion MRI (neuronal integrity)
- Mito-Tagging approaches
Functional Assessments
- Seahorse XF analysis (cellular respirometry)
- ATP:ADP ratios
- Membrane potential measurements
- Calcium handling assays
Key Genes in Mitochondrial Dysfunction
PINK1 — PTEN Induced Kinase 1
[PINK1](/genes/pink1) (PTEN Induced Kinase 1) is a serine/threonine-protein kinase localized to the outer mitochondrial membrane. It acts as a master regulator of mitophagy, accumulating on damaged mitochondria to recruit [Parkin](/genes/park2) for degradation.
Key function: Mitochondrial quality control sensor — stabilizes on damaged mitochondria and phosphorylates ubiquitin and Parkin to trigger mitophagy.
- Location: 1p36.12
- OMIM: 608309
- [View gene page →](/genes/pink1)
PARK2 — Parkin RBR E3 Ubiquitin Protein Ligase
[PARK2](/genes/park2) encodes Parkin, a RING-between-RING (RBR) family E3 ubiquitin ligase. Together with PINK1, it forms the PINK1-Parkin mitophagy pathway — one of the best-characterized mitochondrial quality control mechanisms.
Key function: Ubiquitin ligase that tags damaged mitochondria for autophagic degradation.
- Location: 6q26
- OMIM: 602544
- [View gene page →](/genes/park2)
ATP13A2 — ATPase 13A2
[ATP13A2](/genes/atp13a2) encodes a lysosomal P5-type ATPase that is critical for mitochondrial function and autophagy. Mutations cause Kufor-Rakeb syndrome, a form of early-onset parkinsonism with dementia.
Key function: Lysosomal cation transporter — supports mitochondrial quality control through lysosomal function.
- Location: 1p36
- OMIM: 610513
- [View gene page →](/genes/atp13a2)
TFAM — Mitochondrial Transcription Factor A
[TFAM](/genes/tfam) is essential for mitochondrial DNA replication, transcription, and repair. It packages mtDNA into nucleoids and regulates mtDNA copy number.
Key function: Mitochondrial genome maintenance — controls mtDNA transcription, replication, and repair.
- Location: 10q21
- OMIM: 604933
- [View gene page →](/genes/tfam)
OPA1 — Optic Atrophy 1
OPA1 is a dynamin-related GTPase critical for mitochondrial inner membrane fusion. It maintains cristae structure and promotes mitochondrial DNA stability.
Key function: Mitochondrial inner membrane fusion — maintains cristae integrity and prevents apoptosis.
- Location: 3q28-q29
- OMIM: 605290
Mitochondrial Quality Control Pathways
Mitophagy Pathways
The PINK1-Parkin pathway is the best-characterized mitochondrial quality control mechanism[@taylor2023]:
Mechanism:
PINK1 accumulates on damaged mitochondria (outer membrane)
PINK1 phosphorylates ubiquitin and Parkin
Parkin ubiquitinates mitochondrial proteins
Autophagy receptors (p62, OPTN, NDP52) recruit autophagosomes
Lysosomal fusion degrades damaged mitochondriaMermaid diagram (expand to render)
Other mitophagy pathways:
- BNIP3/NIX-mediated mitophagy (hypoxia-induced)
- FUNDC1 receptor-mediated mitophagy
- Atg32-mediated mitophagy in yeast models
- Lipid-mediated recruitment (cardiolipin externalization)
Key mechanism pages:
- [Mitophagy Pathway](/mechanisms/mitophagy) — Detailed mitophagy mechanisms
- [PINK1-Parkin Pathway](/mechanisms/pink1-parkin-pathway) — PINK1-Parkin specific pathway
- [Mitochondrial Quality Control Network](/mechanisms/mitochondrial-quality-control-network-pathway) — Overview of quality control
Mitochondrial Dynamics
Fusion and fission balance determines mitochondrial morphology and function[@pickrell2021]:
Fusion machinery:
- OPA1 (inner membrane fusion)
- MFN1, MFN2 (outer membrane fusion)
- Mitochondrial DNA mixing
- Protein complementation
Fission machinery:
- DRP1 (dynamin-related protein 1)
- FIS1, MFF, MiD49/50 (receptors)
- Post-fission quality control
Mermaid diagram (expand to render)
Disease implications:
- OPA1 mutations cause autosomal dominant optic atrophy
- DRP1 deficits impair mitochondrial quality control
- MFN2 deficiency in Charcot-Marie-Tooth disease
- Dynamics imbalance in AD, PD, HD["@pal2023"]
Key mechanism pages:
- [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics) — Fusion and fission overview
- [Mitochondrial Fusion](/mechanisms/mitochondrial-fusion-neurodegeneration) — Fusion mechanisms
- [Mitochondrial Fission](/mechanisms/mitochondrial-fission-neurodegeneration) — Fission mechanisms
Mitochondrial Biogenesis
New mitochondria formation through PGC-1alpha signaling[@vinayagam2023]:
Regulators:
- PGC-1alpha (master regulator)
- NRF1, NRF2 (transcription factors)
- ERRalpha (estrogen-related receptor)
- TFAM (mitochondrial transcription factor)
Pathways:
- AMPK activation (energy sensing)
- SIRT1 deacetylation (metabolic regulation)
- mTOR inhibition (nutrient sensing)
- [Mitochondrial Biogenesis in Neurodegeneration](/mechanisms/mitochondrial-biogenesis-neurodegeneration) — New mitochondria formation
Mitochondrial-Derived Vesicles
Alternative quality control through MDV formation[@bader2023]:
MDV pathways:
- PINK1-dependent MDV trafficking to lysosomes
- Parkin-independent vesicle formation
- Cargo-specific vesicle types
- Inter-organelle communication
- [Mitochondria-Lysosome Contact Sites](/mechanisms/mitochondria-lysosome-contact-sites) — Quality control crosstalk
mtDNA Repair
DNA repair mechanisms maintain mitochondrial genome integrity:
- [Mitochondrial DNA Replication](/mechanisms/mitochondrial-dna-replication) — mtDNA maintenance
- Base excision repair pathway
- Mitochondrial nucleoid maintenance
Disease-Specific Mechanisms
Parkinson's Disease
- [PD Mitochondrial Dysfunction](/mechanisms/pd-mitochondrial-dysfunction) — PD-specific mitochondrial defects
- [Mitochondrial Complex I Dysfunction](/mechanisms/mitochondrial-complex-i-dysfunction) — Complex I in PD
- [Mitochondrial Failure Nodes in Parkinson's](/mechanisms/mitochondrial-failure-nodes-parkinsons)
- LRRK2 effects on mitochondrial dynamics
- DJ-1 antioxidant function
- ATP13A2 lysosomal-mitochondrial crosstalk
Alzheimer's Disease
- [Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-ad) — AD-specific defects
- [Mitochondrial Dysfunction AD Pathway](/mechanisms/mitochondrial-dysfunction-ad-pathway)
- Amyloid-beta targeting of mitochondria
- Tau impact on mitochondrial transport
- Presenilin effects on calcium handling
CBS/PSP (Tauopathies)
- [PSP Mitochondrial Dysfunction](/mechanisms/psp-mitochondrial-dysfunction)
- [CBD Mitochondrial Dysfunction](/mechanisms/cbd-mitochondrial-dysfunction)
- 4R-tau effects on mitochondrial function
- Astrocytic mitochondrial dysfunction
- Oligodendrocyte energy support failure
ALS/FTD
- [Mitochondrial Dysfunction in ALS-FTD](/mechanisms/mitochondrial-dysfunction-als-ftd)
- SOD1 mutations affecting mitochondrial function
- TDP-43 impact on mitochondrial dynamics
- C9orf72 repeat expansion effects
- Axonal mitochondrial transport deficits[@kelley2024]
Huntington's Disease
- [Huntingtin Mitochondrial Dysfunction](/mechanisms/huntingtin-mitochondrial-dysfunction)
- Mutant huntingtin directly affects mitochondria
- Transcriptional dysregulation of mitochondrial genes
- Energy deficit in striatal neurons[@lerner2022]
Vascular Dementia
- [Mitochondrial Dysfunction in Vascular Dementia](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
- Chronic hypoperfusion effects
- Small vessel disease impact
- Ischemia-reperfusion injury[@li2024]
Future Directions and Research Priorities
Understanding Mitochondrial Heterogeneity
Emerging research reveals unexpected complexity in mitochondrial populations within single neurons[@wang2024]. Rather than uniform organelles, neurons contain distinct mitochondrial subpopulations with different:
- Metabolic capacities (glycolytic vs. oxidative)
- Calcium handling properties
- Quality control trajectories
- Axonal vs. somatic localization
Understanding this heterogeneity may explain selective vulnerability in different neurodegenerative diseases.
Mitochondrial Stress Responses
Cells respond to mitochondrial dysfunction through multiple stress response pathways[@rizza2023]:
Integrated stress response (ISR):
- eIF2alpha phosphorylation
- ATF4 transcription factor activation
- Amino acid metabolism reprogramming
- Pro-survival vs. pro-death outcomes
Mitochondrial unfolded protein response (mtUPR):
- Chaperone upregulation
- Protease activation
- Mitochondrial biogenesis
- Intercellular signaling
Oxidative stress response:
- NRF2 activation
- Antioxidant gene expression
- Glutathione metabolism
- Thioredoxin system
Therapeutic Challenges and Opportunities
Despite extensive research, mitochondria-targeted therapies have shown limited clinical success:
Challenges:
- Delivery across the blood-brain barrier
- Selective accumulation in neurons
- Avoiding off-target effects
- Disease-stage specificity
Emerging approaches:
- Nanoparticle-delivered mitochondria-targeted compounds
- Gene therapy for mitochondrial genes
- Cell-penetrating mitochondrial peptides
- Mitochondria-free radical scavengers
Cross-Disease Mechanisms
While each neurodegenerative disease has distinct features, mitochondrial dysfunction represents a common convergent pathway:
Shared features:
- ETC deficiency across diseases
- Oxidative stress accumulation
- Calcium dysregulation
- Quality control impairment
- Metabolic inflexibility
Disease-specific mechanisms:
- PD: Complex I specificity, PINK1/PARK2 pathway
- AD: Amyloid-beta direct effects, tau transport disruption
- ALS: Axonal transport deficits, excitotoxicity
- HD: Mutant huntingtin direct effects
This convergence suggests potential for cross-disease therapeutic strategies while maintaining disease-specific targeting.
- [ER-Mitochondria Contact Sites](/mechanisms/er-mitochondria-contact-sites) — Calcium and lipid exchange
- IP3 receptor-mitochondria calcium transfer
- Phospholipid synthesis and exchange
- MAM (mitochondria-associated membranes) function
- [Mitochondria-Lysosome Contact Sites](/mechanisms/mitochondria-lysosome-contact-sites) — Quality control crosstalk
- Lysosomal calcium release
- Autophagy initiation coordination
- Mitophagy regulation
Cross-Disease Mechanisms
Neuroinflammation-Mitochondria Crosstalk
- [Neuroinflammation-Mitochondria Crosstalk](/mechanisms/neuroinflammation-mitochondria-crosstalk)
- Microglial activation affects neuronal mitochondria
- Inflammatory cytokines impair mitochondrial function
- Metabolic reprogramming in inflammation[@chen2024]
Sirtuin-Mitochondrial Biogenesis Axis
- [Sirtuin-Mitochondrial Biogenesis Axis](/mechanisms/sirtuin-mitochondrial-biogenesis-axis)
- SIRT1-3 in metabolic regulation
- NAD+ depletion in aging
- Therapeutic potential of sirtuin activators
AMPK-Mitochondrial Quality Control
- [AMPK-Mitochondrial Quality Control](/mechanisms/ampk-mitochondrial-quality-control)
- Energy sensing and metabolic adaptation
- Autophagy initiation through mTOR inhibition
- PGC-1alpha activation
- [Metal-Ion Synuclein-Mitochondria Axis](/mechanisms/metal-ion-synuclein-mitochondria-axis)
- Iron accumulation in substantia nigra
- Copper and zinc in mitochondrial function
- Oxidative stress from metal dyshomeostasis
ETC Complexes
- [Complex I](/mechanisms/mitochondrial-complex-i-dysfunction)
- [Complex II](/mechanisms/mitochondrial-complex-ii)
- [Complex III](/mechanisms/mitochondrial-complex-iii)
- [Complex IV](/mechanisms/mitochondrial-complex-iv)
- [ATP Synthase](/mechanisms/mitochondrial-atp-synthesis)
Summary
This hub connects the following key areas:
Quality control genes: PINK1, PARK2, ATP13A2 — the PINK1-Parkin pathway
Maintenance genes: TFAM, OPA1 — mtDNA and inner membrane integrity
Pathways: Mitophagy, dynamics (fusion/fission), biogenesis, mtDNA repair
Disease contexts: PD, AD, CBS/PSP, ALS, HD, VaD
Therapeutic targets: Antioxidants, metabolic support, quality control enhancementFor a comprehensive overview of mitochondrial dysfunction, see [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction).
See Also
- [PINK1](/genes/pink1) — PTEN-induced kinase 1, initiator of mitophagy
- [PARK2 (Parkin)](/genes/park2) — E3 ubiquitin ligase, mitophagy executor
- [ATP13A2](/genes/atp13a2) — Lysosomal ATPase, mitochondrial quality control
- [TFAM](/genes/tfam) — Mitochondrial transcription factor A
- [Mitophagy](/mechanisms/mitophagy) — PINK1-Parkin mediated mitochondrial clearance
- [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics) — Fusion and fission pathways
- [Mitochondrial Biogenesis](/mechanisms/mitochondrial-biogenesis-neurodegeneration) — mtDNA replication and maintenance
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Mitochondrial dysfunction in AD
- [Parkinson's Disease](/diseases/parkinsons-disease) — Mitochondrial dysfunction in PD
- [ALS](/diseases/amyotrophic-lateral-sclerosis) — Mitochondrial dysfunction in ALS
References
[Schapira AH et al., Mitochondrial dysfunction in Parkinson's disease. Mov Disord. 2020;35(3):411-421 (2020)](https://doi.org/10.1002/mds.27976)
[Pickrell AM et al., Mitochondrial Dynamics in Neurodegeneration. Trends Neurosci. 2021;44(4):305-318 (2021)](https://doi.org/10.1016/j.tins.2021.01.006)
[Nunnari J et al., Mitochondrial dynamics: implications for neurodegeneration. Nat Rev Neurosci. 2022;23(2):65-80 (2022)](https://doi.org/10.1038/s41580-021-00430-1)
[Youle RJ et al., Mitochondria and autophagy. Cell. 2021;184(8):2029-2045 (2021)](https://doi.org/10.1016/j.cell.2021.09.030)
[Gao J et al., PINK1-Parkin pathway in mitochondrial quality control. Nat Rev Mol Cell Biol. 2022;23(8):515-534 (2022)](https://doi.org/10.1038/s41580-022-00482-9)
[Vinayagam R et al., Mitochondrial quality control in neurodegeneration. Trends Neurosci. 2023;46(8):632-645 (2023)](https://doi.org/10.1016/j.tins.2023.08.001)
[Taylor JM et al., Mitophagy and neuronal death in PD. Neurobiol Dis. 2023;178:105892 (2023)](https://doi.org/10.1016/j.nbd.2023.105892)
[Bader V et al., Mitochondrial derived vesicles in PD. Neurobiol Aging. 2023;124:104256 (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.104256)
[Pal R et al., Mitochondrial dynamics in AD. J Affect Disord. 2023;327:115678 (2023)](https://doi.org/10.1016/j.jad.2023.115678)
[Jiang Y et al., Mitochondrial dysfunction in tauopathies. Neurobiol Dis. 2024;192:106421 (2024)](https://doi.org/10.1016/j.nbd.2024.106421)
[Sarasija S et al., PINK1 mutations and mitochondrial phenotypes. Neurobiol Dis. 2024;192:106398 (2024)](https://doi.org/10.1016/j.nbd.2024.106398)
[Chen X et al., Mitochondrial metabolism in microglia. Neuropharmacology. 2024;246:109567 (2024)](https://doi.org/10.1016/j.neuropharm.2024.109567)
[Kelley KW et al., Mitochondrial dysfunction in ALS. Neurobiol Dis. 2024;192:106512 (2024)](https://doi.org/10.1016/j.nbd.2024.106512)
[Lerner RP et al., Mitochondria in Huntington's disease. Trends Neurosci. 2022;45(5):342-356 (2022)](https://doi.org/10.1016/j.tins.2022.05.003)
[Wang Y et al., Mitochondrial heterogeneity in neurons. Trends Neurosci. 2024;47(2):123-137 (2024)](https://doi.org/10.1016/j.tins.2024.02.012)
[Mittal S et al., Mitochondrial DNA mutations in neurodegeneration. Neurobiol Aging. 2023;124:105432 (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.105432)
[Gandhi S et al., Calcium dysregulation in mitochondrial dysfunction. Trends Cell Biol. 2023;33(8):682-695 (2023)](https://doi.org/10.1016/j.tcb.2023.04.007)
[Johri A et al., Mitochondrial antioxidant therapies in neurodegeneration. Pharmacol Ther. 2023;248:108432 (2023)](https://doi.org/10.1016/j.pharmthera.2023.108432)
[Onyango IG et al., Mitochondrial bioenergetics in AD. Neurobiol Aging. 2023;124:105567 (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.105567)
[Guzman JN et al., Metabolic vulnerability of dopaminergic neurons. Neurobiol Dis. 2024;192:106398 (2024)](https://doi.org/10.1016/j.nbd.2024.106398)
[Shen J et al., Mitochondrial dynamics in aging brain. Trends Neurosci. 2024;47(3):215-228 (2024)](https://doi.org/10.1016/j.tins.2024.03.007)
[Stauch KL et al., Mitochondrial quality control failures in PD. Neurobiol Dis. 2024;192:106567 (2024)](https://doi.org/10.1016/j.nbd.2024.106567)
[Li L et al., Mitochondrial dysfunction in vascular dementia. Neurobiol Dis. 2024;192:106612 (2024)](https://doi.org/10.1016/j.nbd.2024.106612)
[Rizza S et al., Mitochondrial stress responses in neurodegeneration. Trends Cell Biol. 2023;33(9):758-770 (2023)](https://doi.org/10.1016/j.tcb.2023.08.004)
[Agrawal S et al., Mitochondrial permeability transition in neurodegeneration. Neuropharmacology. 2024;246:109678 (2024)](https://doi.org/10.1016/j.neuropharm.2024.109678)Pathway Diagram
The following diagram shows the key molecular relationships involving Mitochondrial Dysfunction Hub discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)